OM
ADAP

Opaleye Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Opaleye Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-40,000
Closed -$326K – 45
2016
Q2 		$326K Sell
40,000
-135,300
-77% -$1.27M 0.22% 48
2016
Q1 		$1.43M Buy
+175,300
New +$1.43M 0.89% 36

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management's ADAP Position: Q3 2016 in Review

Opaleye Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2016, closing a stake of 40,000 shares — an estimated $326K sold.

Opaleye Management first reported a position in ADAP in Q1 2016 and held it in 2 quarters. The position peaked at $1.43M in Q1 2016. 46 funds tracked by Wall St. Rank hold ADAP as of Q3 2016.

  • Opaleye Management reported no remaining Adaptimmune Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Opaleye Management sold 40,000 Adaptimmune Therapeutics shares in Q3 2016, an estimated $326K.
  • Opaleye Management first reported a position in Adaptimmune Therapeutics in Q1 2016 and held it in 2 quarters.
  • Opaleye Management's Adaptimmune Therapeutics position peaked at $1.43M in Q1 2016.
  • 46 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2016.

Based on Opaleye Management's 13F filing for Q3 2016, filed 14 Nov 2016.